PMID- 16005370
OWN - NLM
STAT- MEDLINE
DCOM- 20051027
LR  - 20181201
IS  - 0168-8227 (Print)
IS  - 0168-8227 (Linking)
VI  - 69
IP  - 2
DP  - 2005 Aug
TI  - Beta cell function and response to treatment in Nigerians with Type 2 diabetes 
      mellitus.
PG  - 196-204
AB  - There are scant data from African populations on the association between 
      beta-cell function and response to treatment with oral hypoglycaemic agents in 
      Type 2 diabetes mellitus (T2DM). Fasting plasma C-peptide (FCP) and 
      glucagon-stimulated C-peptide (GSCP) levels were measured in 116 Nigerians with 
      T2DM at a university teaching hospital. After 9 months of follow-up and 
      treatment, they were categorized into three groups based on response to 
      treatment: (A) good control but not on maximum sulphonylurea (SU) therapy, (B) 
      inadequate control but not on maximum SU therapy and (C) on maximum SU 
      therapy+/-insulin or biguanide. Logistic regression models were used to 
      investigate how well C-peptide levels predicted the subjects belonging to Group C 
      who are likely to require insulin. The mean FCP and mean GSCP levels of Group C 
      were significantly lower than in the other groups (p=0.024; p= <0.001 
      respectively). A GSCP cut-off value of < or =1.3 ng/mL predicted membership of 
      Group C with 85% sensitivity and 89% specificity while a cut-off of < or =1.8 
      ng/mL was associated with 91% sensitivity and 66% specificity. In resource-poor 
      settings where inadequate treatment are common, estimation of GSCP may be useful 
      in predicting treatment response and should be weighed against the cost of 
      inadequate therapy with higher morbidity and mortality.
FAU - Oli, J M
AU  - Oli JM
AD  - University of Nigeria Teaching Hospital, Enugu, Nigeria. johnnieoli@hotmail.com
FAU - Adeyemo, A A
AU  - Adeyemo AA
FAU - Okafor, G O
AU  - Okafor GO
FAU - Ofoegbu, E N
AU  - Ofoegbu EN
FAU - Onyenekwe, B
AU  - Onyenekwe B
FAU - Chukwuka, C J
AU  - Chukwuka CJ
FAU - Chen, G
AU  - Chen G
FAU - Chen, Y
AU  - Chen Y
FAU - Doumatey, A P
AU  - Doumatey AP
FAU - Aje, T O
AU  - Aje TO
FAU - Rotimi, C N
AU  - Rotimi CN
LA  - eng
GR  - 3T37TW00041-03S2/TW/FIC NIH HHS/United States
GR  - DK-54001/DK/NIDDK NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, U.S. Gov't, Non-P.H.S.
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - Ireland
TA  - Diabetes Res Clin Pract
JT  - Diabetes research and clinical practice
JID - 8508335
RN  - 0 (Blood Glucose)
RN  - 0 (C-Peptide)
SB  - IM
MH  - Blood Glucose/metabolism
MH  - Body Mass Index
MH  - Body Size
MH  - C-Peptide/blood
MH  - Diabetes Mellitus, Type 2/drug therapy/*physiopathology
MH  - Fasting
MH  - Female
MH  - Humans
MH  - Islets of Langerhans/*metabolism
MH  - Male
MH  - Middle Aged
MH  - Nigeria
EDAT- 2005/07/12 09:00
MHDA- 2005/10/28 09:00
CRDT- 2005/07/12 09:00
PHST- 2004/06/22 00:00 [received]
PHST- 2004/12/17 00:00 [revised]
PHST- 2004/12/22 00:00 [accepted]
PHST- 2005/07/12 09:00 [pubmed]
PHST- 2005/10/28 09:00 [medline]
PHST- 2005/07/12 09:00 [entrez]
AID - S0168-8227(05)00003-3 [pii]
AID - 10.1016/j.diabres.2004.12.006 [doi]
PST - ppublish
SO  - Diabetes Res Clin Pract. 2005 Aug;69(2):196-204. doi: 
      10.1016/j.diabres.2004.12.006.